Gilvetmab is the first and only immune checkpoint inhibitor developed for the treatment of mast cell tumors (MCTs) and melanomas in dogs.
LEARN MORETriple-action, once-a-day treatment for 7 days for even the most stubborn cases associated with susceptible strains of yeast and bacteria in canines.
LEARN MOREA powerful first-line, broad-spectrum topical medication administered twice a day for 7 days to treat otitis external in dogs.
LEARN MOREAn aid in the prevention of pneumonia, diarrhea, septicemia and mortality caused by Salmonella Choleraesuis and as an aid in control of disease caused by…
LEARN MORE